deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT00916747

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies

Sponsor: Boston Children's Hospital

Conditions Progeria
Interventions Lonafarnib, Zoledronic Acid, and Pravastatin
Updated 16 times since 2017 Last updated: Feb 23, 2023 Started: Aug 31, 2009 Primary completion: Feb 28, 2022 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Progeria, this trial is ongoing. The trial is conducted by Boston Children's Hospital and has accumulated 16 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jul 2019 · 11 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Mar 2023 · 9 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 18 months · monthly snapshot

Change History

16 versions recorded

  1. Mar 2025 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  3. Jan 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE2

  5. Feb 2020 — Sep 2020 [monthly]

    Enrolling By Invitation PHASE2

  6. Jul 2019 — Feb 2020 [monthly]

    Enrolling By Invitation PHASE2

  7. Aug 2018 — Jul 2019 [monthly]

    Enrolling By Invitation PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Enrolling By Invitation PHASE2

  9. Jun 2017 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE2

    Status: Active Not Recruiting → Enrolling By Invitation

  10. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boston Children's Hospital
  • Eiger BioPharmaceuticals
  • Merck Sharp & Dohme LLC
  • Schering-Plough
Data source: Boston Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations